-
Clasto-Lactacystin β-lactone: Proteasome Workflows
2026-08-20
Clasto-Lactacystin β-lactone provides a cell-permeable, irreversible way to connect proteasome activity with protein turnover, necroptosis, and viral immune evasion. This workflow-focused guide explains assay design, controls, optimization, and how to interpret RIPK3 degradation experiments without mistaking global proteasome effects for pathway-specific biology.
-
GRE Suppresses Melanogenesis via CREB/MITF Signaling
2026-08-19
The reference study identifies a combination of glabridin, resveratrol, and ellagic acid (GRE) as a multifunctional formulation with anti-melanogenic, antioxidant, and anti-inflammatory activity in cell-based assays. Its main mechanistic contribution is linking reduced melanogenesis to inhibition of CREB phosphorylation and downstream MITF-associated pigmentation programs.
-
Sorafenib: From Kinase Potency to Tumor Models
2026-08-19
Explore how Sorafenib (BAY-43-9006) connects kinase inhibition with angiogenesis, tumor proliferation inhibition, and hepatocellular carcinoma model design. This guide emphasizes assay selection, potency interpretation, and practical experimental controls.
-
Leucovorin Calcium in Gastric Cancer Assays
2026-08-18
Leucovorin Calcium, or calcium folinate, can serve as a mechanistic rescue control in methotrexate studies. This article explains how to use it in patient-derived gastric cancer assembloid assays to separate folate-dependent cytotoxicity from stromal effects.
-
Rat Claustrum Development and Nurr1 Neurogenetic Gradients
2026-08-18
Fang, Wang, and Naumann mapped when Nurr1-positive neurons emerge in the rat claustrum, endopiriform nucleus, and lateral cortex by combining developmental expression analysis with EdU birth dating. Their results resolve regional timing differences and reveal spatial neurogenetic gradients, providing a framework for interpreting claustrum anatomy and designing future developmental labeling studies.
-
CGRP/SP–Piezo2 Signaling in Trigeminal Neuralgia
2026-08-17
Liao et al. identify a Ca2+-dependent CGRP/SP–Piezo2 positive-feedback loop linking trigeminal root compression, neuroinflammation, and mechanical allodynia. Their rat and cellular experiments position the TG neuron–Merkel cell axis as a mechanistic bridge between ATP signaling and pathological mechanotransduction, while also highlighting testable intervention points for trigeminal neuralgia research.
-
FDA 2022 DDI Evidence: Mechanisms and Clinical Relevance
2026-08-17
This analysis of 22 drugs approved by the FDA in 2022 integrates NDA review data, in vitro findings, pharmacokinetic modeling, and clinical drug–drug interaction results to clarify enzyme- and transporter-mediated risk. Its treatment of Oteseconazole as a P-gp and/or BCRP inhibitor illustrates how mechanistic observations can inform labeling and the evaluation of concomitant medications.
-
Heart–Brain Dysregulation in PTSD Mice
2026-08-16
A 2026 European Journal of Pharmacology study identifies a vagus-mediated heart-to-insula pathway linking sympathetic cardiac overactivation with PTSD-like behavior in mice. By combining stress and isoproterenol models with ECG, neural recording, vagotomy, and propranolol treatment, the work provides a mechanistic framework for studying neurocardiac dysfunction while highlighting important limits for translation.
-
miR-18a, ALOXE3, and Ferroptosis in Glioblastoma
2026-08-15
The reference study identifies a miR-18a/ALOXE3 axis that links lipid metabolism to ferroptosis resistance and glioblastoma migration. Its combined cellular, biochemical, and orthotopic mouse experiments suggest that restoring ALOXE3-associated activity could affect both tumor survival and motility, although translation to clinical treatment remains unresolved.
-
Biotin-16-UTP for RNA Labeling and Capture
2026-08-14
Biotin-16-UTP is a biotin-labeled uridine triphosphate for in vitro transcription RNA labeling, affinity capture, and RNA detection and purification. Its documented specifications support controlled RNA-protein interaction studies and RNA localization assays, while the RNASEH1-AS1 literature illustrates how labeled RNA can support mechanistic research without replacing disease-specific validation.
-
10 mM dNTP Mixture: Assay Design Insights
2026-08-14
Explore how a 10 mM dNTP mixture supports controlled DNA synthesis while enabling better assay design for PCR, sequencing, and nucleic acid trafficking studies. This guide connects nucleotide quality, experimental controls, and mechanistic interpretation without confusing DNA production with LNP delivery biology.
-
GRE Suppresses Melanogenesis via CREB/MITF
2026-08-13
The reference study evaluates a combined glabridin, resveratrol, and ellagic acid formulation as a multi-target intervention against melanogenesis, oxidative stress, and inflammatory signaling. Its most important mechanistic finding is that GRE acts beyond direct tyrosinase inhibition, suppressing the upstream CREB/MITF axis in cell-based models and providing a rationale for further pigmentation regulation research.
-
From CYP2C19 Probe to Human Intestinal Models
2026-08-13
A translational framework for using (S)-Mephenytoin as a mechanistic CYP2C19 substrate in hiPSC-derived intestinal organoids, connecting enzyme kinetics with human-relevant pharmacokinetic studies while defining validation requirements and experimental limits.
-
Drug-Sensitized Yeast for mTOR Inhibitor Discovery
2026-08-12
Breen and colleagues developed a genetically drug-sensitized Saccharomyces cerevisiae platform that substantially improves detection of TOR/mTOR pathway inhibitors. The system distinguished known inhibitors, identified aminophylline as a TOR1-dependent growth inhibitor, and found no detectable TOR inhibition for Canagliflozin under the tested yeast conditions.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity
2026-08-12
This study identifies acetylation-dependent control of the core spliceosome protein SmD2 as a determinant of alternative splicing, DNA-repair capacity, and PARP inhibitor response in hepatocellular carcinoma. Its mechanistic model supports combining HDAC2-directed epigenetic modulation with olaparib to expose a therapeutic vulnerability in HCC models.